GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NKGen Biotech Inc (NAS:NKGN) » Definitions » Institutional Ownership

NKGen Biotech (NKGen Biotech) Institutional Ownership : 0.37% (As of May. 27, 2024)


View and export this data going back to 2023. Start your Free Trial

What is NKGen Biotech Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, NKGen Biotech's institutional ownership is 0.37%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, NKGen Biotech's Insider Ownership is 0.87%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, NKGen Biotech's Float Percentage Of Total Shares Outstanding is 27.71%.


NKGen Biotech Institutional Ownership Historical Data

The historical data trend for NKGen Biotech's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NKGen Biotech Institutional Ownership Chart

NKGen Biotech Historical Data

The historical data trend for NKGen Biotech can be seen below:

2023-09-30 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30
Institutional Ownership 0.05 0.05 0.35 0.38 0.38 0.38 0.37

NKGen Biotech Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


NKGen Biotech (NKGen Biotech) Business Description

Traded in Other Exchanges
N/A
Address
19700 Fairchild Road, Suite No. 300, Irvine, CA, USA, 92612
NKGen Biotech Inc is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer cell therapies utilizing our proprietary SNK (super-activated) platform.